Welgene Biotech Co.,Ltd.

Taipei Exchange 6661.TWO

Welgene Biotech Co.,Ltd. EBIT for the year ending December 31, 2023: USD -13.52 K

Welgene Biotech Co.,Ltd. EBIT is USD -13.52 K for the year ending December 31, 2023, a -102.49% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Welgene Biotech Co.,Ltd. EBIT for the year ending December 31, 2022 was USD 541.90 K, a -24.54% change year over year.
Welgene Biotech Co.,Ltd. EBIT for the year ending December 31, 2021 was USD 718.09 K, a -44.52% change year over year.
Welgene Biotech Co.,Ltd. EBIT for the year ending December 31, 2020 was USD 1.29 M, a -1.09% change year over year.
Welgene Biotech Co.,Ltd. EBIT for the year ending December 31, 2019 was USD 1.31 M, a 1.65% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Taipei Exchange: 6661.TWO

Welgene Biotech Co.,Ltd.

CEO	Dr. Yi Xing Lin
IPO Date	Oct. 23, 2017
Location	Taiwan
Headquarters	No. 3, Yuanyuan Street
Employees	80
Sector	Health Care
Industries Biotechnology Research & Consulting

Description

Welgene Biotech Co.,Ltd. provides genetic testing services. The company offers research services, including sequencing, microarray, qPCR verification, nucleic acid extraction/QC, LCM single cell experiment, and bioinformatics analysis services; and Cytoscan, an array-based comparative genomic hybridization. It also provides reagents, consumable supplies, and instruments, as well as software services. The company was founded in 2003 and is based in Taipei City, Taiwan.

Key trends

Past 5 years